LEVETIRACETAM TEVA ® 250 MG

País: Israel

Idioma: anglès

Font: Ministry of Health

ingredients actius:

LEVETIRACETAM 250 MG

Disponible des:

TEVA PHARMACEUTICAL INDUST.LTD

Codi ATC:

N03AX14

formulario farmacéutico:

TABLETS

Vía de administración:

PER OS

Fabricat per:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Grupo terapéutico:

LEVETIRACETAM

indicaciones terapéuticas:

- Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - Levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.- Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patient from 16 years of age with newly diagnosed epilepsy.- Levetiracetam is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Data d'autorització:

2009-09-01